FUSMobile to showcase Neurolyser XR at ASPN 2026

FUSMobile will exhibit its Neurolyser XR at Booth 513 during the ASPN 2026 Annual Conference in Miami and sponsor the event’s hands-on Clinical Lab on July 16, 2026. The demonstration is meant to give pain physicians a practical look at image-guided focused ultrasound for non-invasive neurotomy procedures.

Why it matters: - The ASPN conference gives FUSMobile a focused audience of interventional pain specialists who can evaluate Neurolyser XR in a clinical workflow setting. - The Clinical Lab adds hands-on training, which can help physicians understand how image-guided focused ultrasound may fit into pain care. - Neurolyser XR is positioned as a needle-free alternative to conventional radiofrequency ablation.

What happened: - FUSMobile said it will exhibit Neurolyser XR at Booth 513 during the American Society of Pain and Neuroscience 2026 Annual Conference in Miami. - The company will also sponsor the ASPN Clinical Lab on July 16, 2026. - The Clinical Lab will give physicians a chance to use a fully functional Neurolyser XR system in a procedural environment.

The details: - Participants will perform simulated procedures with fluoroscopic guidance, treatment planning, target localization and focused ultrasound ablation. - The lab will use a specially developed thermochromic phantom that changes color when heated. - The phantom will show the size and location of each ablation in real time. - As the phantom cools, the color returns to its original state. - The reusable model allows repeated treatments and multiple practice sessions. - FUSMobile said the setup provides immediate visual confirmation of treatment accuracy. - Neurolyser XR is an image-guided therapeutic focused ultrasound platform designed for non-invasive neurotomy procedures under fluoroscopic guidance. - The system targets pain-generating nerves with sub-millimeter precision. - The platform is designed to avoid needles, probes and tissue disruption associated with conventional radiofrequency ablation.

Between the lines: - The Clinical Lab format moves the product demo beyond a standard sales presentation and into a workflow-focused training exercise. - The thermochromic phantom is meant to make treatment effects visible, which can help clinicians assess precision and repeatability. - FUSMobile is signaling that education and physician familiarity are part of its go-to-market strategy. - Arik Hananel, FUSMobile’s CEO, said the ASPN meeting is an ideal venue because it brings together leading interventional pain specialists.

What's next: - Conference attendees can visit Booth 513 throughout the meeting for live demonstrations and meetings with the FUSMobile team. - Attendees can also join the Clinical Lab for image-guided treatment planning, targeting and real-time focused ultrasound ablation practice. - FUSMobile said Neurolyser systems are now in clinical use in more than ten countries, including the United States and Canada. - More information is available at FUSMobile's website.